Dhruba Acharya
Southport, QLD, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Intranasal delivery of engineered anti-SARS-CoV-2 extracellular vesicles therapeutically represses lung infection and inflammation.
Journal: Drug delivery and translational research
Published: July 09, 2025
Alterations in cell arrangements of group B streptococcus due to virulence factor expression can bias estimates of bacterial populations based on colony count measures.
Journal: Microbiology (Reading, England)
Published: April 24, 2024
Extracellular Vesicles Loaded with Long Antisense RNAs Repress Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Journal: Nucleic acid therapeutics
Published: March 26, 2024
An opportunistic pathogen under stress: how Group B Streptococcus responds to cytotoxic reactive species and conditions of metal ion imbalance to survive.
Journal: FEMS microbiology reviews
Published: August 31, 2023
Variable resistance to zinc intoxication among Streptococcus agalactiae reveals a novel IS1381 insertion element within the zinc efflux transporter gene czcD.
Journal: Frontiers in immunology
Published: February 27, 2023
Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection.
Journal: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Published: August 25, 2022
Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccine.
Journal: Science advances
Published: October 29, 2021
A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19.
Journal: bioRxiv : the preprint server for biology
Published: April 28, 2021
A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: April 14, 2021
Last Updated: 09/26/2026